How heterogeneous is the clinical manifestation we refer to as “schizophrenia” ?
Based on multiplex immuno-assay readings scientists of the CCNR were able to identify two distinct molecular subgroups of antipsychotica naive schizophrenia patients. The implicated clinical potential was validated in an independant cohort. Not only does this suggest specific molecular profiles defining schizophrenia subtypes, it also underlines the need for personally tailored add-on treatments.